BACK TO 決算

AdaptHealth Corp. Announces Third Quarter 2026 Results

Nov 03, 2026

CONSHOHOCKEN, Pa. – November 3, 2026 - AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the third quarter ended September 30, 2026. 

Third Quarter Business Highlights

  • Made solid progress in the second full quarter of the Company’s exclusive capitated agreement with a large national integrated delivery network, with utilization lower than peak levels and reduced labor costs driving a sequential improvement in contract profitability. 
  • Cleared the Hart-Scott-Rodino waiting period for the pending sale of the Company’s Diabetes Health business for $235.0 million in cash, with the transaction on track to close in early 2027, subject to certain regulatory approvals and other customary closing conditions. 
  • Signed preferred-provider agreements with four health systems, and broadened its capitated portfolio through two smaller agreements with regional health plans, one new and one expanded. 
  • Grew registered myAPP users to more than 615,000, up approximately 88% from year-end 2025, and completed more than 12,600 patient scans with its AI-powered mask-fitting tool. 


Third Quarter Results 

 
All comparisons are to the quarter ended September 30, 2025 unless otherwise stated. The amounts presented below reflect the Company’s continuing operations, except for cash flow from operations and free cash flow, which include the cash flows from continuing operations and discontinued operations, see below for further discussion. 

  • Net revenue was $745.6 million compared to $672.4 million, an increase of 10.9%. 
  • Organic revenue growth of 12.8%, with growth across each of the Company’s reportable segments. 
  • Net loss attributable to AdaptHealth Corp. was $168.2 million compared to net income of $10.2 million, largely resulting from a $184.8 million pre-tax write down of goodwill. 
  • Adjusted EBITDA was $141.9 million compared to $146.1 million, a decrease of 2.9%.  
  • Cash flow from operations was $395.6 million year-to-date 2026, a decrease from $418.6 million during the comparable period in 2025, and free cash flow was $2.6 million year-to-date 2026, compared to $140.1 million during the comparable period in 2025.


Management Commentary 

“In the third quarter, we delivered strong organic revenue growth and exceeded our guidance for revenue, Adjusted EBITDA and free cash flow,” said Suzanne Foster, Chief Executive Officer. “Our capitated partnership made a positive contribution to enterprise Adjusted EBITDA, driven by a tighter labor model and lower costs to serve. We also continue to move toward closing the sale of our Diabetes Health business, bringing us closer to a more focused portfolio built around Sleep Health, Respiratory Health and Wellness-at-Home. The business is stabilizing as we work through a period of transformation, and we look forward to carrying that momentum into 2027.” 

Financial Outlook 

The Company is revising its financial guidance for fiscal year 2026 on a continuing operations basis, which excludes the Diabetes Health business, except for free cash flow, which includes the cash flows from continuing operations and discontinued operations, as follows: 

  • Net revenue of $2.88 billion to $2.90 billion, from $2.85 billion to $2.89 billion 
  • Adjusted EBITDA of $510 million to $525 million, from $490 million to $520 million 
  • Free cash flow of $50 million to $75 million, from $80 million to $120 million 


Conference Call 

Management will host a teleconference today, Tuesday, November 3, 2026, at 8:30 am ET to discuss the results and business activities with analysts and investors.  

Interested parties may participate in the call by dialing:  

When prompted, reference Conference ID: AHCO3Q26 

Webcast registration: Click Here.

Following the live call, a replay will be available for six months on the Company's website, www.adapthealth.com, under "Investor Relations."